Study: Galderma's RelabotulinumtoxinA Earns High Marks from Patients

Study participants reported looking great, more natural,  and feeling happier on the Facial Lines Treatment Satisfaction Questionnaire (FLTSQ) through month six after treatment. 

Galderma's investigational ready-to-use liquid botulinum toxin RelabotulinumtoxinA scored high patient satisfaction and psychological well-being ratings for the treatment of glabellar lines and lateral canthal lines in addition to previously reported safety and efficacy, according to presentations from two Phase 3 studies (READY-1 and READY-2) at the 2022 American Society for Dermatologic Surgery Annual Meeting in Aurora, CO.

Both studies met their primary endpoints, with significantly higher response than placebo after one month for both frown lines and crow's feet.  Results showed rapid onset of action, with 39 percent of patients seeing results on Day 1 for frown lines and 34 percent seeing results on Day 1 for crow's feet. Results also demonstrated long duration of action through six months

Treatment was well tolerated, with all treatment-related adverse events mild-to-moderate and non-serious, the studies showed.Study participants reported looking great, more natural,  and feeling happier on the Facial Lines Treatment Satisfaction Questionnaire (FLTSQ) through month six after treatment. Additionally, subjects reported their psychological well-being (measured by the subject's FACE-Q™ psychological function scores) improved by +11.0 or higher over baseline.

In related news from Galderma,  Sculptra showed long-lasting efficacy out to month 12, with a Galderma Cheek Wrinkle Scales (GCWS at rest) responder rate of 71.6 percent and improved skin radiance, tightness and jawline contour (≥ 86%), The treatment was considered safe and well tolerated in the study, with mostly mild and transient related adverse events resolving.